EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer

Muhammad Zubair Saleem, Ruyi Huang, Yingying Huang, Xin Guo, Yang Liu, Miao Gao, Yinjuan Fan, Zhe-Sheng Chen, Zun-Fu Ke, Shengnan Ye, Jianhua Xu

Drug Resistance Updates · 2025

DOI: 10.1016/j.drup.2025.101226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Muhammad Zubair Saleem und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medica…. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Breast Neoplasms, HSP90 Heat-Shock Proteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Department of Science and Technology, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: TRAP1 is involved in metabolic reprogramming and promotes drug resistance. We aimed to explore whether a novel HSP90 inhibitor, C210, overcomes doxorubicin (DOX) resistance of quiescent breast cancer cells by targeting TRAP1. METHODS: Breast cancer cells were induced to quiescence by hypoxia and low glucose. The relationship of cell metabolism with HSP90 and TRAP1 was investigated by Western blotting, ECAR, OCR, mitochondrial complex activity, and proteomic analysis. The targets of C210 and their functions were analyzed by SPR and immunoprecipitation. The antitumor effect in vivo was investigated with mouse tumor model. RESULTS: In hypoxia and glucose deprivation, breast cancer cells exhibited elevated TRAP1 and an OXPHOS-enhanced quiescent phenotype. These cells were highly resistant to DOX but more sensitive to C210. C210 disrupted TRAP1's interaction with OXPHOS-associated client proteins, prompting proteasome-dependent degradation of these proteins, thereby reducing OCR, mitochondrial ATP production and resulting in selective elimination of the quiescent cancer cells by inducing mitochondrial apoptosis which could be reversed by exogenous ATP. Moreover, C210 targeted glycolytic, amino acid, and β-oxidation-associated proteome. C210 demonstrated promising in vivo anticancer efficacy which was particularly related to OXPHOS inhibition. CONCLUSIONS: C210 eliminates DOX-resistant quiescent breast cancer cells by targeting TRAP1-dependent bioenergetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinDrug Resistance, NeoplasmBreast NeoplasmsHSP90 Heat-Shock ProteinsAntibiotics, AntineoplasticFemaleHumansAnimalsMiceOxidative PhosphorylationCell Line, TumorMitochondriaXenograft Model Antitumor AssaysApoptosisGlucoseProteomicsMCF-7 CellsMetabolic Reprogramming

Stichwörter der Autor:innen

ApoptosisDrug resistanceHSP90Oxidative phosphorylationQuiescenceTRAP1

Substanzen

DoxorubicinHSP90 Heat-Shock ProteinsTRAP1 protein, humanAntibiotics, AntineoplasticGlucose

Autor:innen und Institutionen

  • School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China.
  • The First Affiliated Hospital of Fujian Medical University, Fuzhou 350004, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
  • Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address: kezunfu@mail.sysu.edu.cn.
  • The First Affiliated Hospital of Fujian Medical University, Fuzhou 350004, China. Electronic address: yeshengnan63@fjmu.edu.cn.
  • School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China. Electronic address: xjh@fjmu.edu.c…

Förderung

  • Fujian Provincial Department of Science and Technology
  • National Natural Science Foundation of China

Zitieren

APA

Saleem, M. Z., Huang, R., Huang, Y., Guo, X., Liu, Y., Gao, M., Fan, Y., Chen, Z. S., Ke, Z. F., Ye, S., & Xu, J. (2025). Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101226

Vancouver

Saleem MZ, Huang R, Huang Y, Guo X, Liu Y, Gao M, et al. Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101226

BibTeX
@article{Saleem2025,
  author = {Saleem, Muhammad Zubair and Huang, Ruyi and Huang, Yingying and Guo, Xin and Liu, Yang and Gao, Miao and Fan, Yinjuan and Chen, Zhe-Sheng and Ke, Zun-Fu and Ye, Shengnan and Xu, Jianhua},
  title = {Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101226}
}
Kostenlos starten →